Press Releases

Read Regulatory and non-regulatory press releases

  • All
  • Non-Regulatory
  • Regulatory
Regulatory

Oncology Ventures CEO Peter Buhl Jensen buys shares in the Company

Regulatory

Claus Frisenberg Pedersen, CCO in Oncology Venture buys shares in the Company

Regulatory

Claus Frisenberg Pedersen, CCO in Oncology Venture buys shares in the Company

Regulatory

Peter Buhl Jensen, CEO in Oncology Venture buys shares in the Company

Regulatory

Correction new weekday: Oncology Venture: Notice to Convene Extraordinary General Meeting

Regulatory

Oncology Venture: Notice to Convene Extraordinary General Meeting

Regulatory

Oncology Venture A/S: Publication of financial report Q3 2018

Regulatory

Oncology Venture enters into financing agreement

Non-Regulatory

OV – Update Regarding Participation at Investor Events in Q4 2018

Regulatory

OV – Clinical up-date

Regulatory

OV – OV increases its share capital due to warrant exercise

Non-Regulatory

OV – Oncology Venture requests meeting with FDA to discuss pathway for LiPlaCis and DRP approval in the US

Regulatory

OV – First prostate cancer patient included in Oncology Venture’s Phase 2 study of Irofulven for personalized treatment

Non-Regulatory

OV: Oncology Venture to Participate at Upcoming Investor Events in Q4 2018

Regulatory

OV – Oncology Venture receives authority clearance to expand an ongoing Phase 2 study of LiPlaCis by inclusion of prostate cancer patients

Non-Regulatory

OV – Oncology Venture’s PARP inhibitor Evaluation for Childhood Cancer Passes First Feasibility Steps

Regulatory

OV – Updated LiPlaCis data positions LiPlaCis and its DRP for an FDA Breakthrough Therapy designation application for breast cancer

Non-Regulatory

OV – Oncology Venture to present at InvestorDagen in Copenhagen and invites Investors to join

Non-Regulatory

MPI – DRP predicts drug efficacy in breast cancer patients. New study on cornerstone drug epirubicin published in “Breast Cancer Research and Treatment”

Non-Regulatory

MPI: MPI has now executed transfer of the last tranche of the Oncology Venture shares sold during May